GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 216 filers reported holding GENMAB A/S in Q2 2024. The put-call ratio across all filers is 4.06 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,137,361 | -23.8% | 85,052 | -9.3% | 0.00% | 0.0% |
| Q1 2024 | $2,805,921 | -5.8% | 93,812 | +0.3% | 0.00% | 0.0% |
| Q4 2023 | $2,978,828 | -10.9% | 93,556 | -1.3% | 0.00% | 0.0% |
| Q3 2023 | $3,343,037 | -6.2% | 94,784 | +1.1% | 0.00% | 0.0% |
| Q2 2023 | $3,563,861 | +27.3% | 93,761 | +26.5% | 0.00% | 0.0% |
| Q1 2023 | $2,799,683 | +109262.6% | 74,144 | +22.7% | 0.00% | 0.0% |
| Q4 2022 | $2,560 | -99.9% | 60,415 | +10.1% | 0.00% | 0.0% |
| Q3 2022 | $1,763,000 | +2.2% | 54,862 | +3.3% | 0.00% | 0.0% |
| Q2 2022 | $1,725,000 | +161.4% | 53,098 | +191.1% | 0.00% | – |
| Q1 2022 | $660,000 | +8.0% | 18,243 | +18.1% | 0.00% | – |
| Q4 2021 | $611,000 | +135.0% | 15,451 | +160.0% | 0.00% | – |
| Q3 2021 | $260,000 | +20.4% | 5,942 | +12.5% | 0.00% | – |
| Q2 2021 | $216,000 | +0.5% | 5,282 | 0.0% | 0.00% | – |
| Q4 2020 | $215,000 | – | 5,282 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 214,848 | $6,980,000 | 2.38% |
| Cutter & CO Brokerage, Inc. | 119,956 | $3,897,000 | 1.33% |
| Hardman Johnston Global Advisors LLC | 933,449 | $30,328,000 | 1.29% |
| Connective Portfolio Management, LLC | 18,000 | $585,000 | 1.00% |
| Capricorn Fund Managers Ltd | 148,411 | $4,822,000 | 0.88% |
| TORRAY INVESTMENT PARTNERS LLC | 131,708 | $4,279,000 | 0.82% |
| First Light Asset Management, LLC | 160,885 | $5,227,000 | 0.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 1,857 | $57,189,000 | 0.60% |
| Yorktown Management & Research Co Inc | 10,100 | $328,000 | 0.42% |
| Integrated Investment Consultants, LLC | 18,550 | $602,000 | 0.22% |